Guest User 8/11/26 Guest User 8/11/26 City Therapeutics Appoints Keith Regnante, MBA, as Chief Financial Officer and Mary Beth DeLena, J.D., as Chief Legal Officer Read More Guest User 6/8/26 Guest User 6/8/26 City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics Read More Guest User 5/6/26 Guest User 5/6/26 City Therapeutics Presents Preclinical Data on Next-Generation Investigational RNAi Therapy CITY-RBP4 for Treatment of Stargardt Disease at ARVO 2026 Annual Meeting Read More
Guest User 8/11/26 Guest User 8/11/26 City Therapeutics Appoints Keith Regnante, MBA, as Chief Financial Officer and Mary Beth DeLena, J.D., as Chief Legal Officer Read More
Guest User 6/8/26 Guest User 6/8/26 City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics Read More
Guest User 5/6/26 Guest User 5/6/26 City Therapeutics Presents Preclinical Data on Next-Generation Investigational RNAi Therapy CITY-RBP4 for Treatment of Stargardt Disease at ARVO 2026 Annual Meeting Read More
